Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This Undiscovered Low Float Stock has the Potential to be the next Multi Billion Dollar Company .RDHL is a MUST HAVE Biotech .
Upcoming Big Milestones:
Results from Phase 3 of Blockbuster Candidate RHB 105 (H. pylori ) coming IN JUNE
Results from Phase 3 of Bekinda (gastroenteritis and gastritis) in 2H 2015
EU Approval for Rizaport (Mirgaine) expected for 2H 2015
EU Approval for Bekinda (oncology support) expected for 2H 2015
Redhill (RDHL)
MarketCap: $147 Million
Cash: $32.6 Million
Shares Out: 9.94 Million
RedHill Biopharma: Undervalued Company With Huge Potential Catalyst
http://seekingalpha.com/article/3140296-redhill-biopharma-undervalued-company-with-huge-potential-catalyst
Ceo Interview
http://wallstreetanalyzer.com/red-hill-biopharma-nasdaqrdhltaserdhl-ceo-interview/
HUGE Pipeline
http://www.redhillbio.com/
Presentation May 2015
http://files.shareholder.com/downloads/AMDA-1C0OBF/165404371x0x825826/5687CCC8-BDF7-42E5-B662-54442BC03018/RedHill_Biopharma_Presentation_May_2015__043015_.p df
RHB-105: Top-line results from the first Phase III H. pylori eradication study- expected mid-end of June 2015 .Market Size: U.S. market is estimated at approximately $1-1.5 billion*
BEKINDA™ (RHB-102): Feedback from UK MHRA regarding European marketing application for oncology support- H2/2015.Market Size: Worldwide market for serotonin (5-HT3) receptor inhibitors is estimated at $900 million**
RIZAPORT™ (RHB-103): Feedback from Germany's BfArM regarding the European marketing application for migraines- H2/2015.The target market for RIZAPORT™, estimated at approximately $870 million*
RIZAPORT™ (RHB-103): A new PDUFA date expected from the FDA for previously filed NDA- H2/2015
BEKINDA™ (RHB-102): Top-line results from the Phase III study in acute gastroenteritis and gastritis- H2/2015.Worldwide potential market could exceed $650 million annually*
RHB-104: Top-line interim results from Phase IIa study for Multiple Sclerosis- H2/2015.Market Size: Worldwide market of over $14 billion*
(RDHL) A MUST HAVE BIOTECH GEM with a lot of Big News in 2015 !
This Low Float Stock has the Potential to be the next Multi Billion Dollar Company .
2 Mega Phase 3 results expected in June and 2H 2015
2 EU Approvals expected in 2H 2015
Redhill (RDHL)
MarketCap: $147 Million
Cash: $32.6 Million
Shares Out: 9.94 Million
Presentation May 2015
http://files.shareholder.com/downloads/AMDA-1C0OBF/165404371x0x825826/5687CCC8-BDF7-42E5-B662-54442BC03018/RedHill_Biopharma_Presentation_May_2015__043015_.pdf
RHB-105: Top-line results from the first Phase III H. pylori eradication study- expected mid-end of June 2015 .Market Size: U.S. market is estimated at approximately $1-1.5 billion*
BEKINDA™ (RHB-102): Feedback from UK MHRA regarding European marketing application for oncology support- H2/2015.Market Size: Worldwide market for serotonin (5-HT3) receptor inhibitors is estimated at $900 million**
RIZAPORT™ (RHB-103): Feedback from Germany's BfArM regarding the European marketing application for migraines- H2/2015.The target market for RIZAPORT™, estimated at approximately $870 million*
RIZAPORT™ (RHB-103): A new PDUFA date expected from the FDA for previously filed NDA- H2/2015
BEKINDA™ (RHB-102): Top-line results from the Phase III study in acute gastroenteritis and gastritis- H2/2015.Worldwide potential market could exceed $650 million annually*
RHB-104: Top-line interim results from Phase IIa study for Multiple Sclerosis- H2/2015.Market Size: Worldwide market of over $14 billion*
PDP.V // MC $ 24 M / Approval for Asthma Drug in June
Pediapharm (PDP.V) has already 6 Products on the Market .The Market Cap of C$ 24 Million is a Big Joke
The Asthma Drug is currently the biggest Drug of Pediapharm if approved in 2Q then the Company will reach profitability quickly .Another Drug called Naproxen Suspension licensed from Roche launched last Month so the Revenue will rise significantly in the coming months .This Stock has everything to be the next 10 bagger .GLTA
Market Cap c$24 Million
Cash c$7.5 Million
Shares Out : 72.1 Million
Insider & Institutions held around 48 Million Shares
Pediapharma Marketed Products
http://www.pedia-pharm.com/en/products/
The Easyhaler®-budesonide filing is currently under review by Health Canada after clearing the screening process in July 2014. Given the internal Health Canada timelines for such a dossier, the Company remains confident to obtain marketing approval by end of June 2015.
Easyhaler-Budesonide (*) Orion-Finland Asthma Market Size $195 M EST.LAUNCH Q-3 2015
Pediapharm Inc. Announces the Launch of Pediapharm Naproxen Suspension in Canada
Pediapharm expects that the product will be available to patients in March 2015 as it plans to start shipping products to wholesalers and key retailers in late February 2015.
http://www.pedia-pharm.com/en/press-releases/pediapharm-inc-announces-the-launch-of-pediapharm-naproxen-suspension-in-canada/
Pure Chinese fraud this junk could be halted by SEC any day now and then say goodbye to your money .
New Presentation
http://telestatherapeutics.com/cms/phpjDm0WL.pdf
Investment Opportunity
•New management team has led transformative change
•Focused on unencumbered, late stage, near-commercial asset for bladder cancer
•BLA filing targeted in Q2/2015 with potential US approval in Q1/2016
•Significant dialogue with US FDA to minimize regulatory risk
•Independent assessment of U.S. market opportunity, market access and pricing
•MCNA specialty product profile validated by 3rd party expressions of interest
•Multiple opportunities to create shareholder value through the achievement of significant regulatory milestones, potential partnering or company sale before or after the US FDA’s BLA decision
GBIM starts to move --- This super low float gem could reach $100 if the Hepatitis Phase 2 results in 2Q is positive .The Partner for the Drug is the World Class Biotech Gilead so positive outcome is highly likely .GL
Market Cap $45 M
Cash $17 M
Price $8
http://ih.advfn.com/p.php?pid=staticchart&s=N%5EGBIM&p=0&t=19&vol=1
This ULTRA low float (Only 2.5 M Shrs) could explode like ESPR on upcoming Hepatitis Phase 2 Results in 2Q if positive . The Drug is partnered with World Class Biotech Gilead so its highly likely that the results will be positive .
GBIM undiscovered and Cheapest Hepatitis Play you can get on the Stockmarket . Important Phase 2 Results of their Hep B Drug (partnered with Gilead) in 2Q if Positive then you can expect a share price explsoion because of its extreme low float .
Globeimmune (GBIM)
Market Cap: $42 Million
Cash $17 Million
Price $7.30
Shares Out: 5.7 Million
GBIM is the Cheapest Hepatitis Play you can get on the Stockmarket with a laughable Market Cap of $42 Million and $17 Million in Cash . GBIM is partnered with World Class Biotechs Gilead and Celgene and Celgene is the largest Shareholder of this undiscovered Goldmine . There are only 5.7 Million Shares Outstanding means if Phase 2 results are positive then this one will explode like a Nuclear bomb .GL
GS-US-330-0101, or the 0101 trial, is a randomized Phase 2 clinical trial, initiated in 2013, investigating GS-4774 in combination with ongoing oral antiviral treatment in patients with chronic HBV infection. The 0101 trial is a multicenter, multinational trial that enrolled 175 patients in a randomized, open-label design comparing three different doses of GS-4774, administered in combination with oral antiviral therapy versus antiviral treatment alone. The primary endpoint for this trial is decline in serum HBV surface antigen, or HBsAg. The 0101 trial is fully-enrolled, and 48-week results are expected to be available in the first half of 2015. These results may be submitted to an upcoming scientific conference.
We have two strategic collaborations with leading biotechnology companies. In October 2011, Gilead Sciences, Inc., or Gilead, exclusively licensed product candidates intended to treat chronic hepatitis B virus, or HBV, infection. Celgene Corporation, or Celgene, entered into a collaboration and option agreement for certain oncology product candidates in May 2009. Under this agreement, in July 2013 Celgene exercised its option for a worldwide, exclusive license to the GI-6300 program, which is a Tarmogen program targeting the brachyury protein. Brachyury plays a role in the metastatic progression of certain cancers and is believed to be fundamental in the formation of chordomas, rare bone tumors of the spine. Through March 31, 2014, we have received over $60 million from these collaborations.
GBIM undiscovered and Cheapest Hepatitis Play you can get on the Stockmarket . Important Phase 2 Results of their Hep B Drug (partnered with Gilead) in 2Q if Positive then you can expect a share price explsoion because of its extreme low float .
Globeimmune (GBIM)
Market Cap: $42 Million
Cash $17 Million
Price $7.30
Shares Out: 5.7 Million
GBIM is the Cheapest Hepatitis Play you can get on the Stockmarket with a laughable Market Cap of $42 Million and $17 Million in Cash . GBIM is partnered with World Class Biotechs Gilead and Celgene and Celgene is the largest Shareholder of this undiscovered Goldmine . There are only 5.7 Million Shares Outstanding means if Phase 2 results are positive then this one will explode like a Nuclear bomb .GL
GS-US-330-0101, or the 0101 trial, is a randomized Phase 2 clinical trial, initiated in 2013, investigating GS-4774 in combination with ongoing oral antiviral treatment in patients with chronic HBV infection. The 0101 trial is a multicenter, multinational trial that enrolled 175 patients in a randomized, open-label design comparing three different doses of GS-4774, administered in combination with oral antiviral therapy versus antiviral treatment alone. The primary endpoint for this trial is decline in serum HBV surface antigen, or HBsAg. The 0101 trial is fully-enrolled, and 48-week results are expected to be available in the first half of 2015. These results may be submitted to an upcoming scientific conference.
We have two strategic collaborations with leading biotechnology companies. In October 2011, Gilead Sciences, Inc., or Gilead, exclusively licensed product candidates intended to treat chronic hepatitis B virus, or HBV, infection. Celgene Corporation, or Celgene, entered into a collaboration and option agreement for certain oncology product candidates in May 2009. Under this agreement, in July 2013 Celgene exercised its option for a worldwide, exclusive license to the GI-6300 program, which is a Tarmogen program targeting the brachyury protein. Brachyury plays a role in the metastatic progression of certain cancers and is believed to be fundamental in the formation of chordomas, rare bone tumors of the spine. Through March 31, 2014, we have received over $60 million from these collaborations.
test 4
test 3
Test 2
Test
BNHLF is close to new 52W high and its still brutally undervalued with a Market Cap of around C$63 Million (= US$49.6 Million ) .GL
Telesta Therapeutics – (TST on TSX) (OTC BNHLF )
Presentation Time - Wednesday April 1st – 11:40 AM ET
Website - http://telestatherapeutics.com
Current Market Cap – Approx. $63 M
Telesta is a late stage therapeutics company with near term commercial potential focused on a unique specialty drug (MCNA) for non-muscle invasive bladder cancer. The drug has completed a phase III study and the Company expects to file it biologics application license (BLA) with the FDA in Q2 of 2015.
Additional Highlights
The US FDA has reviewed the Company’s clinical data and is supportive of a BLA filing with no additional trials.
MCNA is a high margin biologic opportunity for Telesta that will be priced as a premium oncology product. The market size has been validated by an independent 3rd party and this market is significant.
The Company has very strong intellectual property coverage with a patent term that would expire in 2031 along with secondary protection of 12 years with US market exclusivity for novel biologic.
There has not been a new treatment for this type of cancer approved by the FDA since 1998.
Who cares what the ANALysts says they follow their own agenda .
This Stock is brutal undervalued and if the interim results are positive in April then you wish you bought at this ridiculous low price .
Smart people buying at the bottom like now( stock still trading below cash balance) and selling high thats the way to make money .
Phase 3 interim results ciming in April and a new Product acquisition/In-licencing also coming anytime now .
So it couldnt be a better time to be in AEZS .
first P3 interim results expected for April .. Ceo says that a few days ago at the Roth Presentation (below) .
http://wsw.com/webcast/roth29/register.aspx?conf=roth29&page=aezs&url=http://wsw.com/webcast/roth29/aezs/index.aspx
AEZS breakout imminent ....
Stock still trading wayy below cash . If the Phase 3 results are similar like those from Phase 2 then we will have here an 10 bagger easily .GL
Market Cap: $53 Million
Cash: $68 Million
Price: 0.59
from tuesdays conference call :
As you know we had, albeit small each of them, but two successful Phase 2 studies behind zoptarelin doxorubicin. In addition to endometrial cancer, we had one in ovarian cancer. Both trials, although conducted separately, demonstrated very favorable side effect profile, no reported cardio toxicity and they both also indicated overall survival of the 15 months compared to standard doxorubicin, the literature as you may recall is around seven to nine months, so it is very promising and we have a full plan of lifecycle management behind this compound based upon success in our current program in endometrial cancer we would then proceed into further indication development and working to really develop this molecule for applications making it a very important tool in the hands of oncologists and for their patients in a number of barriers in oncology
----
Results from a PII study in 43 patients with LHRH-positive advanced endometrial cancer were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Patients received AEZS-108 267 mg/m2 by IV infusion over 2 hours, with retreatment every 3 weeks, for up to 6 courses. The primary endpoint was response rate based on RECIST criteria. 2 patients had a complete response (CR; 5.1%), 10 a partial response (PR; 25.6%), and 17 stable disease (SD; 43.6%), giving an Overall Response Rate (ORR = CR+PR) of 30.8 % and a Clinical Benefit Rate (CBR = CR+PR+SD) of 74.4%; responses were seen in patients who had prior platinum/taxane chemotherapy. Median time to progression and overall survival were 7 months and 14.3 months, respectively .
AEZS very HOT now
Dilution (already closed) here created a fantastic buying opportunity for Gamblers . Big Phase 3 data for Endometrial Cancer coming in April this could push the sp significantly higher . AEZS is Trading below Cash so the downside is very limited thats why the stock is very attractive for Gamblers .GL
Market Cap : $50 Million
Cash: ~ $65 Million
Price: $0.51
Maxim Maintains Buy On Aeterna Zentaris Ahead Of Zoptarelin-Dox Data
In a research report sent to investors today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) with a $2.00 price target, which implies an upside of 251% from current levels.
Kolbert said, “Zoptarelin-Dox data (interim analysis) in 1H15 represents a key event for the company. We believe that the incremental improvements to this standard of care agent should make it a low risk, high probability of positive outcome event.”
---------------
Zoptarelin Doxorubicin
–Potentially the first FDA approved medical therapy for treating
recurrent endometrial cancer
Interim results in H1-2015 (~128 events)
Significant Market Opportunity Potential
Estimated Potential Annual Market Value
Medical Therapy Treating Recurrent Endometrial Cancer
North America $300–$400 Million
Europe $150–$250 Million
AEZS is Debt FREE and Trading at Cash level this is what counts not the deficit they make in last years .
Most unprofitable Biotechs have similar or higher accumulated deficit but this doesnt matter .
BNHLF Rating Update
Im sure that we will see higher share price than the PT below of $1.25 before FDA decision .GL
Market Cap: $42 Million
Price:0.25
We (Euro Pacific Capital) are initiating coverage on Telesta Therapeutics (formerly Bioniche Life Sciences) with a Speculative BUY rating and one-year target price of $1.25. The firm’s lead non-muscle invasive bladder cancer biologic MCNA (described below) already performed well in Phase III testing, well enough to be FDA approved by next year in our view, and our model is primarily derived from free cash flow projections in global markets for this imminently partnerable (and acquirable) clinical asset. Investment Highlights Attractive oncology drug developer for which already-published Phase III data mitigates clinical risk .
We value Telesta using the average of three methods as shown in Exhibit 16; an NPV determination based on our 10-year MCNA-derived free cash flow projections, 20x multiple of our F2019 EPS forecast, and 12.5x EV/EBITDA multiple, with all methods discounted by 30%, a rate that is if anything conservative for a clinical asset for which clinical risk has already been greatly attenuated by already-published Phase III
data. As we indicated above, we forecast fully-diluted, fully-taxed EPS of $0.15 and adjusted EBITDA of
$54.6M in our F2019 reference year. From the average of the three methods, we derive a $1.38 price target, which we conservatively round down to $1.25.
BNHLF Analyst Rating
Looks like m´Major Breakout is on the way .GL
Telesta Therapeutics Inc. was rated new “speculative buy” at Euro Pacific Canada. The 12-month target price is $1.25 (Canadian) per share.
BNHLF (MC $41 M) UPDATE
Still one of the Cheapest Cancer Play out there with a ridiculous Market Cap of $41 Million a lifetime opportunity here .GL
Presentation February
http://www.telestatherapeutics.com/cms/phpP7aOHe.pdf
Summary
•Under-the-radar Canadian public company with little/no exposure to
U.S./Institutional investors
US BLA submission targeted for Q2/2015 – potential approval in Q1/2016
•De-risked through significant interaction with US FDA <<<<<<<<<<<<<<
US peak market estimate $400 million with comparable market opportunity ex-US
New and focused senior management team and board has transformed the
company
•Unencumbered, late stage, near-commercial uro-oncology asset
•Very favourable specialty pharma product profile
•Patent protection potential to 2031
•Strong competitive position – no late stage competition
•Significant 3rd party interest in this asset
The Company also reported that there is significant 3rd party interest in the MCNA program and that it is in receipt of multiple non-binding expressions of interest from a variety of public and private pharmaceutical and biotechnology companies. Due to the confidential nature of the ongoing discussions, Telesta will only provide further updates to shareholders upon signature of a binding agreement.
Dr. Michael Berendt, CEO & Chief Scientist of Telesta cautioned that: "We will fully evaluate and negotiate the current offers to ensure that if we take the decision to partner MCNA or sell the company at this juncture, that such a decision will capture significant value for our investors."
AEZS.. Phase 3 interim Results in 1H 2015 this could be a real 10 Bagger . Stock trading at Cash Level .
Aeterna Zentaris (AEZS)
Market Cap: $44 M
Cash: $42 M
Price: $0.67
If Phase 3 is really positive then this Stock will explode like KERX or ACAD did .GL
Maxim Maintains Buy On Aeterna Zentaris Ahead Of Zoptarelin-Dox Data
In a research report sent to investors today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) with a $2.00 price target, which implies an upside of 251% from current levels.
Kolbert said, “Zoptarelin-Dox data (interim analysis) in 1H15 represents a key event for the company. We believe that the incremental improvements to this standard of care agent should make it a low risk, high probability of positive outcome event.”
---------------
Zoptarelin Doxorubicin
–Potentially the first FDA approved medical therapy for treating
recurrent endometrial cancer
Interim results in H1-2015 (~128 events)
Significant Market Opportunity Potential
Estimated Potential Annual Market Value
Medical Therapy Treating Recurrent Endometrial Cancer
North America $300–$400 Million
Europe $150–$250 Million
IDT acquired 23 FDA APPROVED Generics with Huge Market Potential ($460 Million) a few weeks ago ,and they have a own Cancer Drug a generic version of Temozolomide under review by FDA which is partnered with Mayne Pharma .
There is strong interest by potential commercialisation partners for the newly acquired Generics . IDT will bring these Drugs with a Partner or more back to the US-Market as soon as possible .
This Undiscovered stock is BRUTAL undervalued with a ridiculous Market Cap of $29 Million . This is minimum a Potential 10 Bagger Gem . GL
IDT Australia (IDT)
Market Cap: $29 Million
Cash: $7 Million
Price: $0.15
Burn-Rate: ~$1.4 Million per Quarter
Annual Rev: $13.5 Millionen
Product Presentation
http://idt.live.irmau.com/IRM/Company/ShowPage.aspx/PDFs/1234-10000000/InvestorInformationregardingANDAAcquisitions
As announced to the ASX on 3 November 2014, the new product suite comprises 23 tablet and capsule products for conditions including Parkinson’s Disease,depression, infection,hypertension and pain. The total current annual global market for these products in these presentations is approximately $460 million (IMS).
In parallel with the integration of these drugs into IDT’s manufacturing facility, the Company is also in discussions with over half a dozen potential commercialisation partners interested in US distribution of the products. Interest has been strong and indicative term sheets have already been received from several of these parties. It is the Company’s expectation that IDT will select one or more commercialisation partners and execute US distribution deal(s) for the initial cohort of products in early to mid 2015.
IDT Completes Transformational AcquisitionOf 23 US Generic Drugs..
http://idt.live.irmau.com/IRM/Company/ShowPage.aspx/PDFs/1256-10000000/Acquisition23USGenericDrugscompleted
US distribution for its generic Temozolomide product ..
http://idt.live.irmau.com/IRM/Company/ShowPage.aspx/PDFs/1193-10000000/USproductdistribution
Temozolomide is indicated for the treatment of melanoma and glioblastoma multiforme and had US sales of approximately USD 340 million in the 12 months ending 31 May 2014 .
The Abbreviated New Drug Application (ANDA) submission for Temozolomide is the first of IDT’s generic filings (ASX announcement 18 November 2013). It has now been accepted for
review by the United States Food and Drug Administration (FDA) and is currently progressing through the FDA’s review process.
Hey Bob i have one question
Can you buy stocks directly on ASX (Australia) ?
I ask you that because i found a very attractive biotech there so i would post the details about the stock if you can buy it .Thanks
BNHLF (MC $33 M) BLA Filing for BIG Bladder Cancer vaccine in this Quarter .
Runup to FDA decision and Approval could drive this Stock close or over $2 per Share ! GL
Market Cap: $33 Million
Cash: $10 Million
Price: $0.19
Bioniche Life Sciences Receives Coverage as Highly Undervalued Biopharmaceutical ...
http://finance.yahoo.com/news/bioniche-life-sciences-receives-coverage-141921899.html
Company Presention
http://www.bioniche.com/pdf/2014/CEO%20Presentation%202014%20Annual%20General%20Meeting.pdf
Bioniche will file BLA with the US FDA, seeking approval for the commercialization of MCNA based on existing clinical data; Target filing date: Q1/2015 . Near term revenue opportunity in the U.S
Potential for marketing approval as early as end of 2015/early 2016 .Exploring potential for US listing .
Pivotal phase 3 study (completed) shows it can delay (or prevent) need for cystectomy (bladder removal) in 25% of patients with high-risk non-muscle invasive bladder cancer (NMIBC) who failed first line BCG treatment
Supported by strong intellectual property coverage
•Patent term expiration: 2031
•Automatic 12 year market exclusivity for novel biologic in US
Of all cancers, bladder cancer has the greatest lifetime treatment cost per patient diagnosed (US, 2010)
$230,000 . 80,000 new cases/year in North America .
Potential for peak U.S. sales of $200M plus .Comparable or greater market opportunity ex-US
•NMIBC BCG-failure population only
•50% market penetration
•$3,000 per dose
BNHLF (MC $33 M) BLA Filing for BIG Bladder Cancer vaccine in this Quarter . A Potential 10+ Bagger !
Runup to FDA decision and Approval could drive this Stock close or over $2 per Share ! GL
Telesta Therapeutics (TST.TO) ....(BNHLF)
Market Cap: $33 Million
Cash: $10 Million
Price: $0.19
Bioniche Life Sciences Receives Coverage as Highly Undervalued Biopharmaceutical..
http://finance.yahoo.com/news/bioniche-life-sciences-receives-coverage-141921899.html
Presention from last month
http://www.bioniche.com/pdf/2014/CEO%20Presentation%202014%20Annual%20General%20Meeting.pdf
Bioniche will file BLA with the US FDA, seeking approval for the commercialization of MCNA based on existing clinical data; Target filing date: Q1/2015 . Near term revenue opportunity in the U.S
Potential for marketing approval as early as end of 2015/early 2016 .Exploring potential for US listing .
Pivotal phase 3 study (completed) shows it can delay (or prevent) need for cystectomy (bladder removal) in 25% of patients with high-risk non-muscle invasive bladder cancer (NMIBC) who failed first line BCG treatment
Supported by strong intellectual property coverage
•Patent term expiration: 2031
•Automatic 12 year market exclusivity for novel biologic in US
Of all cancers, bladder cancer has the greatest lifetime treatment cost per patient diagnosed (US, 2010) $230,000 . 80,000 new cases/year in North America .Potential for peak U.S. sales of $200M plus .
Comparable or greater market opportunity ex-US
•NMIBC BCG-failure population only
•50% market penetration
•$3,000 per dose
BNHLF (MC $33 M) BLA Filing for BIG Bladder Cancer vaccine in this Quarter . A Potential 10+ Bagger !
Runup to FDA decision and Approval could drive this Stock close or over $2 per Share ! GL
Telesta Therapeutics (TST.TO) ....(BNHLF)
Market Cap: $33 Million
Cash: $10 Million
Price: $0.19
Bioniche Life Sciences Receives Coverage as Highly Undervalued Biopharmaceutical..
http://finance.yahoo.com/news/bioniche-life-sciences-receives-coverage-141921899.html
Presention from last month
http://www.bioniche.com/pdf/2014/CEO%20Presentation%202014%20Annual%20General%20Meeting.pdf
Bioniche will file BLA with the US FDA, seeking approval for the commercialization of MCNA based on existing clinical data; Target filing date: Q1/2015 . Near term revenue opportunity in the U.S
Potential for marketing approval as early as end of 2015/early 2016 .Exploring potential for US listing .
Pivotal phase 3 study (completed) shows it can delay (or prevent) need for cystectomy (bladder removal) in 25% of patients with high-risk non-muscle invasive bladder cancer (NMIBC) who failed first line BCG treatment
Supported by strong intellectual property coverage
•Patent term expiration: 2031
•Automatic 12 year market exclusivity for novel biologic in US
Of all cancers, bladder cancer has the greatest lifetime treatment cost per patient diagnosed (US, 2010) $230,000 . 80,000 new cases/year in North America .Potential for peak U.S. sales of $200M plus .
Comparable or greater market opportunity ex-US
•NMIBC BCG-failure population only
•50% market penetration
•$3,000 per dose
BNHLF (MC $33 M) BLA Filing for BIG Bladder Cancer vaccine in this Quarter .
Runup to FDA decision and Approval could drive this Stock close or over $2 per Share ! GL
Market Cap: $33 Million
Cash: $10 Million
Price: $0.19
Presention fron last month
http://www.bioniche.com/pdf/2014/CEO%20Presentation%202014%20Annual%20General%20Meeting.pdf
Bioniche will file BLA with the US FDA, seeking approval for the commercialization of MCNA based on existing clinical data; Target filing date: Q1/2015 . Near term revenue opportunity in the U.S
Potential for marketing approval as early as end of 2015/early 2016 .Exploring potential for US listing .
Pivotal phase 3 study (completed) shows it can delay (or prevent) need for cystectomy (bladder removal) in 25% of patients with high-risk non-muscle invasive bladder cancer (NMIBC) who failed first line BCG treatment
Supported by strong intellectual property coverage
•Patent term expiration: 2031
•Automatic 12 year market exclusivity for novel biologic in US
Of all cancers, bladder cancer has the greatest lifetime treatment cost per patient diagnosed (US, 2010) $230,000 . 80,000 new cases/year in North America .Potential for peak U.S. sales of $200M plus .
Comparable or greater market opportunity ex-US
•NMIBC BCG-failure population only
•50% market penetration
•$3,000 per dose
BNHLF (MC $33 M) BLA Filing for BIG Bladder Cancer vaccine in this Quarter .
Runup to FDA decision and Approval could drive this Stock close or over $2 per Share ! GL
Market Cap: $33 Million
Cash: $10 Million
Price: $0.19
Presention fron last month
http://www.bioniche.com/pdf/2014/CEO%20Presentation%202014%20Annual%20General%20Meeting.pdf
Bioniche will file BLA with the US FDA, seeking approval for the commercialization of MCNA based on existing clinical data; Target filing date: Q1/2015 . Near term revenue opportunity in the U.S
Potential for marketing approval as early as end of 2015/early 2016 .Exploring potential for US listing .
Pivotal phase 3 study (completed) shows it can delay (or prevent) need for cystectomy (bladder removal) in 25% of patients with high-risk non-muscle invasive bladder cancer (NMIBC) who failed first line BCG treatment
Supported by strong intellectual property coverage
•Patent term expiration: 2031
•Automatic 12 year market exclusivity for novel biologic in US
Of all cancers, bladder cancer has the greatest lifetime treatment cost per patient diagnosed (US, 2010)
$230,000 . 80,000 new cases/year in North America .
Potential for peak U.S. sales of $200M plus .Comparable or greater market opportunity ex-US
•NMIBC BCG-failure population only
•50% market penetration
•$3,000 per dose
BNHLF (MC $33 M) BLA Filing for BIG Bladder Cancer vaccine in this Quarter .
Runup to FDA decision and Approval could drive this Stock close or over $2 per Share ! GL
Market Cap: $33 Million
Cash: $10 Million
Price: $0.19
Presention fron last month
http://www.bioniche.com/pdf/2014/CEO%20Presentation%202014%20Annual%20General%20Meeting.pdf
Bioniche will file BLA with the US FDA, seeking approval for the commercialization of MCNA based on existing clinical data; Target filing date: Q1/2015 . Near term revenue opportunity in the U.S
Potential for marketing approval as early as end of 2015/early 2016 .Exploring potential for US listing .
Pivotal phase 3 study (completed) shows it can delay (or prevent) need for cystectomy (bladder removal) in 25% of patients with high-risk non-muscle invasive bladder cancer (NMIBC) who failed first line BCG treatment
Supported by strong intellectual property coverage
•Patent term expiration: 2031
•Automatic 12 year market exclusivity for novel biologic in US
Of all cancers, bladder cancer has the greatest lifetime treatment cost per patient diagnosed (US, 2010)
$230,000 . 80,000 new cases/year in North America .
Potential for peak U.S. sales of $200M plus .Comparable or greater market opportunity ex-US
•NMIBC BCG-failure population only
•50% market penetration
•$3,000 per dose
DYNT unknown EBOLA gem
Market Cap $10 M
Price $4
Shares Outstanding : 2.5
Float 1.8 M
Investors have appeared particularly interested recently in stocks associated with either treatment or diagnosis of the Ebola virus. One such company is Dynatronics Corporation (DYNT), which is responsible for developing non-contact digital thermometers that can be used by the Transportation Security Administration to screen air passengers, hence reducing the risk of catching the virus from an Ebola victim.
VSR ..EBOLA UNKNOWN GEM ...
Market Cap only $47 M
Shares Out : 9.7 M
Revenue $110 M
Their Products
http://www.versarpps.com/products/onesuit%C2%AE-et
VSR ..undiscovered EBOLA stock .. Low Float Gem with HUGE Upside Potential like LAKE .GL
Market Cap ridiculous $45 M
Revenue $110+ M
Shares Outstanding 8.5 M
VSR ..EBOLA UNKNOWN GEM ...
Market Cap only $47 M
Shares Out : 8 M
Revenue $110 M
Their Products
http://www.versarpps.com/products/onesuit%C2%AE-et
GOVX (MC $7 M) .VERY HOT EBOLA GEM which is unknown , just 10 M shares on the float /50% held by Management / O/S only 25 M
GOVX (MC $7 M) .VERY HOT EBOLA GEM which is unknown , just 10 M shares on the float /50% held by Management / O/S only 25 M
GOVX (MC $7 M) .VERY HOT EBOLA GEM which is unknown , just 10 M shares on the float /50% held by Management / O/S only 25 M
FDA DECISION IN 2 DAYS
Downside risk $1-1.50
Upside Potential $10+